Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908176 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study of Avapritinib and Midazolam
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04908176 is a Phase 1 study that has completed, run by Blueprint Medicines Corporation. The registered enrollment target is 10 participants.
The verdict
NCT04908176, a Phase 1 study, has completed, sponsored by Blueprint Medicines Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
Interventions
- DRUG Avapritinib
- DRUG midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2024-05-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908176
The ClinicalTrials.gov registry entry for NCT04908176 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avapritinib is the first listed.
NCT04908176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908176 about?
NCT04908176 is a clinical study titled "A Drug-drug Interaction Study of Avapritinib and Midazolam". The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), recurrent gliomas, or other KIT mutant tumors.
What is the current status of trial NCT04908176?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-08-24. Estimated completion is 2024-05-10.
What interventions are being tested in trial NCT04908176?
The interventions under investigation include: Avapritinib (DRUG), midazolam (DRUG).
Who is sponsoring clinical trial NCT04908176?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.